EClinCloud Scales AI-Driven Clinical Research Platform to 1,100 Trials

The platform integrates essential research functions—including electronic data capture, randomization, and clinical trial management—onto one data model and workflow engine. By eliminating the need for disparate point systems, the software allows project teams to view data in real time and maintain continuous audit trails. This consolidation aims to replace the common industry practice of stitching together software from multiple providers, which often results in operational silos.

Central to the company's growth is its focus on AI-native engineering. The platform uses specialized agents to automate study builds, a process the company claims reduces manual effort by roughly 60%. Additionally, its medical OCR technology achieves over 95% accuracy in source data capture across a vast array of form types. These tools are backed by ISO/IEC 42001:2023 certification for AI management and strict adherence to global regulatory frameworks, including HIPAA, GDPR, and ICH GCP.

Founder and CEO Michael Qin noted that the platform was engineered from inception to meet international standards, drawing on experience from China’s high-volume research environment. With a diverse client base comprising 54% pharmaceutical firms, 23% biotechs, and 17% contract research organizations, the company is now leveraging its offices in New York and across China to support multi-regional studies with 24/7 multilingual operations.